Literature DB >> 1873789

Angiofollicular lymph node hyperplasia (Castleman's disease) in an adolescent female. Clinical and immunologic findings.

G V Massey1, M J Kornstein, D Wahl, X L Huang, C W McCrady, R A Carchman.   

Abstract

Angiofollicular lymph node hyperplasia is a heterogeneous disorder of unclear etiology and has a wide spectrum of systemic symptoms. This report describes a case of this disorder in a 15-year-old girl and examines the response of the primary mass, systemic symptoms, and alterations of selected immune parameters at diagnosis, as a result of steroid therapy and radiation therapy (RT). The patient had a 1-year history of growth failure, delayed puberty, and refractory iron deficiency anemia. Computed tomography scan showed a posterior mediastinal mass. Biopsy revealed angiofollicular lymph node hyperplasia of mixed hyaline-vascular and plasma cell type histologic type. Immunoperoxidase studies showed polyclonal B-cells, predominance of T-helper cells (CD4) over cytotoxic/suppressor T-cells (CD8), and the presence of natural killer (NK) cells. Southern blot analysis demonstrated germ line gene configuration for the T-cell antigen receptor and Ig heavy chain. The patient clinically improved with RT after failing to respond to steroids. Immunophenotyping of peripheral blood lymphocytes before therapy revealed a CD4:CD8 ratio of 0.8 with decreased numbers of circulating T-cells; this increased to 1.4 after steroid therapy. The patient's T-lymphocytes had no proliferative response to phytohemagglutinin (PHA) or concanavalin A (Con A) before RT. After RT, a small but significant mitogenic response to these reagents was noticed. The proliferative response to recombinant interleukin-2 (rIL-2) remained similar to that of control lymphocytes. Induction of second messenger signals by activation of protein kinase C (PKC) and elevation of free cytosolic calcium through the use of the phorbol ester, phorbol 12, 13-dibutyrate (PDBu), and ionomycin (Io) resulted in a strong proliferative response at diagnosis and after RT. In vitro cytotoxicity assays revealed diminished NK activity before and after therapy. Lymphokine-activated killer (LAK) activity remained comparable with that of control cells and was not affected by therapy. Before RT patient lymphocytes maintained cytotoxic capabilities after coincubation with rIL-2 and PDBu plus Io, whereas coincubation with these reagents abrogated cytotoxic function of normal cells. This case demonstrates a clinical response to RT as well as improvement in immune parameters. Intact signal transduction mechanisms through PKC activation and elevation of cytosolic calcium were also demonstrated in the circulating lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873789     DOI: 10.1002/1097-0142(19910915)68:6<1365::aid-cncr2820680630>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Castleman's disease in childhood: report of three cases and review of the literature.

Authors:  Piero Farruggia; Antonino Trizzino; Nunzia Scibetta; Giovanni Cecchetto; Patrizia Guerrieri; Emanuele S G D'Amore; Paolo D'Angelo
Journal:  Ital J Pediatr       Date:  2011-10-20       Impact factor: 2.638

2.  Unicentric Castleman's disease of the pancreas with massive central calcification.

Authors:  Oliver Goetze; Matthias Banasch; Klaus Junker; Wolfgang E Schmidt; Christian Szymanski
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

Review 3.  Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature.

Authors:  Iris A C de Vries; Marjolein M S van Acht; Thomas B J Demeyere; Marnix L M Lybeert; Jean-Paul de Zoete; Grard A P Nieuwenhuijzen
Journal:  Radiat Oncol       Date:  2010-02-02       Impact factor: 3.481

4.  Cases report of unicentric Castleman's disease: revisit of radiotherapy role.

Authors:  O Kyu Noh; Sang-Wook Lee; Jae Whan Lee; Sang Yoon Kim; Chung Soo Kim; Eun Kyung Choi; Jong Hoon Kim; Seung Do Ahn
Journal:  Radiat Oncol J       Date:  2013-03-31

Review 5.  Treatment of Castleman's disease.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2005-05

6.  International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

Authors:  Frits van Rhee; Eric Oksenhendler; Gordan Srkalovic; Peter Voorhees; Megan Lim; Angela Dispenzieri; Makoto Ide; Sophia Parente; Stephen Schey; Matthew Streetly; Raymond Wong; David Wu; Ivan Maillard; Joshua Brandstadter; Nikhil Munshi; Wilbur Bowne; Kojo S Elenitoba-Johnson; Alexander Fössa; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Sheila K Pierson; Amy Greenway; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Amy Chadburn; David C Fajgenbaum
Journal:  Blood Adv       Date:  2020-12-08

Review 7.  Update and new approaches in the treatment of Castleman disease.

Authors:  Kah-Lok Chan; Stephen Lade; H Miles Prince; Simon J Harrison
Journal:  J Blood Med       Date:  2016-08-03

8.  Castleman disease.

Authors:  Ibrahiem Saeed-Abdul-Rahman; Ali M Al-Amri
Journal:  Korean J Hematol       Date:  2012-09-25

Review 9.  Castleman's disease in the head of the pancreas: report of a rare clinical entity and current perspective on diagnosis, treatment, and outcome.

Authors:  Hongbei Wang; Rosemary L Wieczorek; Michael E Zenilman; Fidelina Desoto-Lapaix; Bimal C Ghosh; Wilbur B Bowne
Journal:  World J Surg Oncol       Date:  2007-11-20       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.